

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
 - This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
 - Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
 - The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
 - The “Description” section describes the Service.
 - The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
 - The “Resources” section lists the information and materials we considered in developing this PCG
 - **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
 - Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.
-

Medical Necessity Requirements for: **Droxidopa** generic and **NORTHERA** (droxidopa)

Criteria for Initial Therapy:

Prescriber Qualifications

- Prescribed by a Neurologist, Nephrologist, or Cardiologist, or is in consultation with one

Indication

- Symptomatic neurogenic orthostatic hypotension (NOH)

Age Requirement

- 18 years or older

ORIGINAL EFFECTIVE DATE: 01/22/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

Baseline Clinical Evaluation

- Neurogenic orthostatic hypotension (NOH) is caused by **ONE** of the following conditions:
 - Parkinson's disease
 - Multiple system atrophy
 - Pure autonomic failure
 - Dopamine beta hydroxylase deficiency
 - Non diabetic neuropathy
- Has persistent and consistent symptoms of orthostatic dizziness, lightheadedness, or feeling about to black out
- Orthostatic hypotension is documented after 5 minutes of supine rest and within 2 to 5 minutes upon standing or head up tilt on a tilt table as **ONE** of the following:
 - Systolic blood pressure decreases at least 20 millimeters of mercury
 - Diastolic blood pressure decreases at least 10 millimeters of mercury

Alternative Therapies

- Failure (at least a 30 day trial), contraindication per FDA label, intolerance, or is not a candidate for simultaneous use of fludrocortisone **AND** midodrine

Brand Specific Criteria

- **For Northera and other generic droxidopa:** Have failure (at least a 30 day trial), contraindication per FDA label or intolerance to **generic droxidopa by CivicaScript**. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- There is no renal impairment (glomerular filtration rate less than 30 mL/min)
- Not currently using nonspecific monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine, tranylcypromine, linezolid)

Additional Requirements

- Nonpharmacologic measures have been maximized that include:
 - Intake of fluid and salt has been liberalized or maximized, where appropriate
 - Uses fitted elastic/compression stockings or abdominal binder, unless contraindicated or not tolerated
 - Head of the bed has been elevated
 - Has been instructed on how to change position from supine to standing in gradual stages
- A comprehensive medication review has been performed to either reduce or discontinue agents that contribute or cause orthostatic hypotension, if clinically safe to do so

Documentation Requirements

- A completed request form must be submitted including:
 - Chart notes
 - Lab results (blood pressure measurements and renal function)
 - Supporting clinical documentation

Initial Therapy Criteria Approval Duration

- 1 month, renewal requires documentation of reduction in orthostatic symptoms **and** an increase in blood pressure for approval

ORIGINAL EFFECTIVE DATE: 01/22/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

Criteria for Continuation of Therapy (renewal therapy):

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.

Prescriber Qualification

- Continues to be seen by a Neurologist, Nephrologist, or Cardiologist, or is in consultation with one

Clinical Response

- Achieved and sustains reduction in dizziness, lightheadedness, feeling faint, or feeling about to black out
- Increase in systolic blood pressure of 10 millimeters of mercury within 3 minutes of standing

Adherence

- Adherence to the prescribed therapy regimen and nonpharmacologic measures has been documented

Brand Specific Criteria

- **For Northera and other generic droxidopa:** Have failure (at least a 30 day trial), contraindication per FDA label or intolerance to **generic droxidopa by CivicaScript**. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- There is no renal impairment (glomerular filtration rate less than 30 mL/min)
- Not currently using nonspecific monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine, tranylcypromine, linezolid)
- Has not developed significant adverse drug effects such as:
 - Persistent supine hypertension
 - Neuroleptic Malignant Syndrome like reaction with hyperpyrexia and confusion
 - Exacerbation of symptoms of existing ischemic heart disease, arrhythmias, and congestive heart failure
 - Hypersensitivity reactions (anaphylaxis, angioedema, bronchospasms, urticaria, rash) dues to FD&C Yellow number 5 (tartrazine) dye

Additional Requirements

- Nonpharmacologic measures have been maximized that include:
 - Intake of fluid and salt has been liberalized or maximized, where appropriate
 - Uses fitted elastic/compression stockings or abdominal binder, unless contraindicated or not tolerated
 - Head of the bed has been elevated
 - Has been instructed on how to change position from supine to standing in gradual stages
- A comprehensive medication review has been performed to either reduce or discontinue agents that contribute or cause orthostatic hypotension, if clinically safe to do so

Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values confirming safe use

Continuation Therapy Criteria Approval Duration

- 6 months OR end of plan year

ORIGINAL EFFECTIVE DATE: 01/22/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
2. Off-Label Use of Cancer Medications

Description:

Generic droxidopa or brand Northera (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF)], dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. The effectiveness of droxidopa beyond 2 weeks of treatment has not been established, continued effectiveness of droxidopa should be assessed periodically.

Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, which is extensively distributed throughout the body. It is believed to exert its effects through norepinephrine and not through the parent molecule. Norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction.

Use of droxidopa is associated with a risk of increased blood pressure while lying down (supine hypertension), individuals must sleep with their head and upper body elevated. In addition, it may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.

Orthostatic hypotension:

- Orthostatic hypotension may be categorized as neurogenic or non-neurogenic in origin
- Non-neurogenic causes include disorders that result in cardiac impairment, reduced intravascular volume and electrolyte loss, venous pooling/vasodilation, and iatrogenic from use of numerous medications
 - Age related orthostatic hypotension is considered a non-neurogenic cause of orthostatic hypotension
- Neurogenic causes include Parkinson's disease (PD), pure autonomic failure (PAF), and multiple system atrophy (MSA)
- Orthostatic hypotension is a physical finding and is defined as a documented decrease of ≥ 20 millimeters of mercury (mmHg) in systolic blood pressure (SBP) or a ≥ 10 mmHg decrease in diastolic blood pressure (DBP) within 3 minutes upon standing or a head-up tilt on a tilt table
- Symptoms of orthostatic hypotension include dizziness, lightheadedness, blurred vision, fatigue and fainting when a person stands

ORIGINAL EFFECTIVE DATE: 01/22/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

- There are known predisposing factors that cause or contribute to orthostatic hypotension such as dehydration, deconditioning, poor nutrition, aging, and others, as well as numerous drugs such as diuretics, antihypertensive agents, anti-anginal agents, antidepressants, alpha-blockers, and others
- Management of orthostatic hypotension involves liberalizing and maximizing fluid and sodium intake (where appropriate), elevation of head of the bed, a comprehensive review of medications used to reduce the doses or discontinue agents that contribute to orthostatic hypotension (if safe to do so), patient education on how to change position from supine to standing in gradual stages, and use of fitted elastic stockings
- Pharmacologic agents used to treat orthostatic hypotension include fludrocortisone and midodrine
- Midodrine is the only other FDA-approved medication for symptomatic orthostatic hypotension
 - Midodrine is a direct acting agonist for peripheral alpha-1 adrenoreceptors
 - It is a pro-drug that is activated to desglymidodrine, the active receptor agonist
 - Desglymidodrine is 15 times more potent than the parent compound and is primarily responsible for the therapeutic effect
 - The pressor effect is due to both arterial and venous constriction
 - The dose should be titrated from 2.5 mg to 10 mg three times a day
- Fludrocortisone is commonly used off-label to treat orthostatic hypotension
 - Fludrocortisone, is a synthetic mineralocorticoid, is considered agent of first choice for orthostatic hypotension and is used in individuals who are not able to increase plasma volume effectively with liberalized fluid and salt intake
 - It has a long duration of action and is well-tolerated by most individuals
 - Fludrocortisone increases blood volume and enhances the sensitivity of blood vessels to circulating catecholamines
 - Other potential actions include enhancing norepinephrine release from sympathetic neurons and increasing vascular fluid content
 - Treatment is initiated with a 0.1 mg tablet and can be increased to 1 mg daily although little benefit is obtained by increasing beyond 0.5 mg daily
- Other off-label treatments that are less commonly used include ephedrine, desmopressin, dihydroergotamine, erythropoietin, indomethacin, octreotide, pyridostigmine, and yohimbine

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Resources:

Northera (droxidopa) product information, revised by Lundbeck Pharmaceuticals, LLC. 07-2019. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed October 30, 2025.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

Droxidopa oral NORTHERA™ (droxidopa) oral

Droxidopa product information, revised by Ajanta Pharma USA, Inc. 11-2021. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed October 30, 2025.

Palma JA, Kaufmann H. Mechanisms, causes, and evaluation of orthostatic hypotension. In: UpToDate, Aminoff MJ, Goddeau RP (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated August 16, 2024. Accessed January 13, 2026.

Palma JA, Kaufmann H. Treatment of orthostatic and postprandial hypotension. In: UpToDate, Aminoff MJ, Kowey P, Goddeau RP (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated August 16, 2024. Accessed January 13, 2026.

ORIGINAL EFFECTIVE DATE: 01/22/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.